Article
Clinical screening assay for EGFR exon 19 mutations using PNA-clamp smart amplification process version 2 in lung adenocarcinoma.
Oncology reports - 1 Nov 2011
Araki Takuya, Shimizu Kimihiro, Nakamura Tomonori, Baba Masaru, Kawai Yuki, Nakamura Katsunori, Mitani Yasumasa, Obayashi Kyoko, Aomori Tohru, Fujita Yukiyoshi, Miyamae Yohei, Kakegawa Seiichi, Kaira Kyoichi, Lezhava Alexander, Hayashizaki Yoshihide, Takeyoshi Izumi, Yamamoto Koujirou
Abstract excerpt
The presence of EGFR mutations is correlated with a positive therapeutic response to tyrosine kinase inhibitors; therefore, the accurate detection of EGFR mutations is crucial when deciding appropriate therapeutic strategies. Recently, the rapid and sensitive assay smart amplification process version 2 (SmartAmp2) was developed. However, this method can only detect one type of mutation in EGFR exon 19; therefore,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.